BAX Baxter Internationaldata gap · 74% coveragelimited data
Health Care · Health Care Equipment · close $25.28 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Baxter International (BAX) has a ThetaGrade House Rating of 37/100 (grade D), ranking #87 of 150 in Health Care. Its strongest pillars are valuation (88) and growth (41); its weakest is profitability (14). Data gap: 4 factors without usable data, so 74% of the method weight is covered. TTM revenue growth is 5.4% and operating margin -2.4%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 74% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 41| Revenue growth YoY (TTM) (22.2%) | 5.4% | 26 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | 2.4% | 72 |
Profitability
weight 18.5% (→20.0%) · 14| Operating margin (10.7%) | -2.4% | 22 |
| 4Q gross-margin change (9.3%) | -5.2% | 4 |
Balance sheet
weight 18.5% (→20.0%) · 17| Net debt / EBITDA (10.7%) | 10.31× | 4 |
| Current ratio (5.3%) | 1.95 | 42 |
| Interest coverage (4.0%) | -0.94× | 19 |
Cash flow
weight 12.33% (→13.3%) · 38| FCF margin (6.7%) | 3.0% | 26 |
| FCF yield (6.7%) | 2.5% | 49 |
Valuation
weight 12.33% (→13.3%) · 88| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 1.77× | 88 |
Technicals (EOD)
| RSI(14) | 59.5 |
| EMA 9 / 21 | 24.79 / 24.45 · crossed up 5d ago |
| 200-day SMA | 21.11 |
| Volume vs 20d avg | 0.65× |
| 20-day return | 9.8% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: net debt/EBITDA above 4×
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpense · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like BAX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is BAX's House Rating?
- BAX scores 37 out of 100 (grade D) as of 2026-10-16, ranking #87 of 150 Health Care stocks we cover.
- What do analysts say about BAX?
- We do not have enough analyst-sentiment data to score this stock.
- When does BAX report earnings next?
- We do not have a reliable estimate for BAX's next earnings date (irregular SEC filing history); a rough window is 2026-10-21 to 2026-11-06. Check the company's investor-relations page.
- Is BAX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology